Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
- REGN-COV2 is Regeneron?s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.
- The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
- Under this collaboration, the overall capacity of REGN-COV2 is expected to increase by at least three and a half times, substantially increasing the number of doses available to patients in the U.S. and around the world.
- Launching COVID-19 diagnostic tests for active infection and the detection of antibodies in patients who have been exposed to the virus,
- Investigating treatments from our existing portfolio to better understand their potential to treat patients with COVID-19,
- Increasing manufacturing and supply chain capacity to meet product demand across our portfolio within the wider context of COVID-19 treatment, and
- Ensuring the supply of our existing medicines and diagnostics to patients around the world under exceptional conditions.
|Dr. Nicolas Dunant Phone: +41 61 687 05 17||Patrick Barth Phone: +41 61 688 44 86|
|Daniel Grotzky Phone: +41 61 688 31 10||Karsten Kleine Phone: +41 61 682 28 31|
|Nina M?hlitz Phone: +41 79 327 54 74||Nathalie Meetz Phone: +41 61 687 43 05|
|Barbara von Schnurbein Phone: +41 61 687 89 67|
|Roche Investor Relations|
|Dr. Karl Mahler Phone: +41 61 68-78503 e-mail:?[email protected]||Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail:?[email protected]|
|Dr. Sabine Borngr?ber Phone: +41 61 68-88027 e-mail:?[email protected]||Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail:?[email protected]|
|Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail:?[email protected]||Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail:?[email protected]|
|Investor Relations North America|
|Loren Kalm Phone: +1 650 225 3217 e-mail:?[email protected]||Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail:?[email protected]|